Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.

IGA scores The likelihood of achieving IGA scores ≤1 was significantly higher for secukinumab‐treated patients than either etanercept‐ or ustekinumab‐treated patients in Subgroups 1, 2 and 3 (ustekinumab‐treated patients only) but did not reach statistical significance in Subgroup 4 (Tables 5 and 6 for etanercept and ustekinumab, respectively).

also in 111,027 other papers